European Panel Backs Schering-Idec Drug
From Reuters
A new cancer treatment from German drug maker Schering and Idec Pharmaceuticals Corp. of San Diego was recommended for approval by a European panel of experts.
The Committee for Proprietary Medicinal Products gave a positive opinion on Zevalin, a treatment for non-Hodgkin’s lymphoma, at its monthly meeting, the London-based European Medicines Evaluation Agency said.
Schering shares rose 85 cents to $44.60 on the New York Stock Exchange. Idec shares fell 49 cents to $34.84 on Nasdaq.
